NFKB1 and melanoma: Amiri et al. [59] demonstrated that exposure to TMZ increased RelA nuclear localization in melanoma cells and that bortezomib, an inhibitor of proteasome able to impair NF-κB activation [60], potentiated TMZ-induced suppression of melanoma cell growth both in vitro and in a murine xenograft model.